Clincosm LogoSign in Get a demo

advanced malignancies

Showing 1 - 25 of 67
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignancies Trial in Guangzhou (BRY812 for injection)

Not yet recruiting
  • Advanced Malignancies
  • BRY812 for injection
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital，Sun Yat-sen University
Sep 7, 2023

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Advanced Cancer, Advanced Malignancies, Bladder Cancer Trial (AB598, Zimberelimab, Carboplatin)

Not yet recruiting
  • Advanced Cancer
  • +11 more
  • (no location specified)
May 26, 2023

Advanced Malignancies, Solid Tumor, Hematological Malignancy Trial in Canton, Gettysburg, West Valley City (Pelabresib)

Recruiting
  • Advanced Malignancies
  • +2 more
  • Canton, Ohio
  • +6 more
Jan 30, 2023

Advanced Malignancies, Non-small-cell Lung Cancer Trial in Worldwide (PF-06801591)

Active, not recruiting
  • Advanced Malignancies
  • Non-small-cell Lung Cancer
  • Beijing, Beijing, China
  • +51 more
Jan 11, 2023

Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)

Recruiting
  • Advanced Malignancies
  • +4 more
  • Fayetteville, Arkansas
  • +61 more
Jan 10, 2023

Advanced Malignancies, Metastatic Cancer Trial in Worldwide (INCAGN01876, Nivolumab, Ipilimumab)

Completed
Has Results
  • Advanced Malignancies
  • Metastatic Cancer
  • Los Angeles, California
  • +37 more
Dec 6, 2022

Recurrent Cancer, Metastatic Cancer, Advanced Malignancies Trial (INCAGN01876, retifanlimab)

Recruiting
  • Recurrent Cancer
  • +3 more
  • INCAGN01876
  • retifanlimab
  • Birmingham, Alabama
  • +17 more
Dec 13, 2022

Advanced Malignancies Trial in Belgium, Spain, United States (INCA32459-101)

Recruiting
  • Advanced Malignancies
  • Los Angeles, California
  • +14 more
Dec 1, 2022

Advanced Malignancies Trial in Beijing (IBI939, IBI939+ Sintilimab)

Active, not recruiting
  • Advanced Malignancies
  • Beijing, China
    Peking University Cancer Hospital & Institute
Oct 4, 2022

Advanced Malignancies Trial in Worldwide (MBG453, PDR001, Decitabine)

Terminated
  • Advanced Malignancies
  • Baltimore, Maryland
  • +13 more
Sep 20, 2022

Advanced Malignancies Trial in Beijing (IBI322)

Active, not recruiting
  • Advanced Malignancies
  • IBI322
  • Beijing, China
    Cancer hospital Chinese academy of Medical sciences
Sep 15, 2022

Advanced Malignancies Trial in Shanghai (IBI110, IBI110+ Sintilimab)

Recruiting
  • Advanced Malignancies
  • Shanghai, China
    Shanghai Pulmonary Hospital
Sep 13, 2022

Advanced Malignancies Trial in Denmark, Hungary, Russian Federation (BI-1808, Pembrolizumab 25 Mg/mL Solution for Injection)

Recruiting
  • Advanced Malignancies
  • BI-1808
  • Pembrolizumab 25 Mg/mL Solution for Injection
  • Copenhagen, Denmark
  • +11 more
Sep 9, 2022

Advanced Malignancies Trial in United States (parsaclisib)

Completed
  • Advanced Malignancies
  • Tustin, California
  • +3 more
Aug 16, 2022

Advanced Malignancies, Advanced Cancer Trial in United States (ASP7517, Pembrolizumab)

Recruiting
  • Advanced Malignancies
  • Advanced Cancer
  • Atlanta, Georgia
  • +3 more
Aug 2, 2022

Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma Trial in United States (PLX2853)

Completed
  • Small Cell Lung Cancer
  • +7 more
  • Scottsdale, Arizona
  • +4 more
Jul 20, 2022

All Malignancies, Advanced Malignancies, Hematologic Malignancy Trial in Spain, United States (Tazemetostat, Itraconazole,

Active, not recruiting
  • All Malignancies
  • +11 more
  • Encinitas, California
  • +9 more
May 20, 2022

Advanced Malignancies Trial in Beijing (BR105 injection)

Not yet recruiting
  • Advanced Malignancies
  • BR105 injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Apr 24, 2022

Advanced Malignancies Trial in Worldwide (Pemigatinib, Retifanlimab, Pembrolizumab)

Recruiting
  • Advanced Malignancies
  • Santa Monica, California
  • +6 more
Apr 6, 2022

Advanced Malignancies Trial in United States (parsaclisib)

Completed
  • Advanced Malignancies
  • Rialto, California
  • +4 more
Mar 28, 2022

Advanced Malignancies Trial in Harbin (TWP-102 injection)

Recruiting
  • Advanced Malignancies
  • TWP-102 injection
  • Harbin, Heilongjiang, China
    Harbin Medical University Cancer Hospital
Mar 7, 2022

Advanced Malignancies Trial in Worldwide (Tislelizumab 200 mg, IV, Pamiparib 20, 40, 60 mg PO Twice Daily (BID), Pemetrexed 500

Enrolling by invitation
  • Advanced Malignancies
  • Tislelizumab 200 mg, IV
  • +4 more
  • Miami Beach, Florida
  • +50 more
Mar 4, 2022

Advanced Malignancies Trial in Tianjin (IBI397, IBI397+Sintilimab, IBI397+Rituximab)

Not yet recruiting
  • Advanced Malignancies
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Feb 8, 2022

Advanced Malignancies Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL95)

Recruiting
  • Advanced Malignancies
  • Recombinant Humanized Monoclonal Antibody MIL95
  • Beijing, China
    Beijing Cancer Hospital
Feb 14, 2022